Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer
NCT05038098Phase 1Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2026
- Primary completion
- Feb 2027
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of FerroTrace in gastric adenocarcinoma (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety of endoscopic peritumoral gastric injection of FerroTrace. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
FerroTrace
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT05038098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038098.